Biotechnology. Scored on the same transparent model behind the daily rankings.
★
TGTX
TG Therapeutics, Inc. · Biotechnology
48.3Score
$55.37Oct 9 close$8.5B
1Y Target$69.71Analyst consensus · 7 analysts
5Y Target$102.07Compound horizon
10Y Target$151.41Long-dated conviction
FCF$17mTTM · 06/26C-
FCF $17m — barely positive; fragile cash position · TTM from SEC filings (OCF − CapEx), four quarters to 06/26.
Rev+76.1%TTM YoYA
Revenue +76.1% — hypergrowth, top decile · Latest four quarters of revenue vs the four before them, from SEC filings.
D/E1.25C
D/E 1.25 — more levered than most Healthcare peers (≈90th pctile)
P/E19.4xB+
P/E 19.4 — below the Healthcare median (≈40th pctile)
PEG*——
PEG n/a — analysts expect next year's earnings to be no higher than last year's
* PEG n/a — analysts expect next year's earnings to be no higher than last year's
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 48.3
Quality58.1
Growth71.8
Value27.1
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week high
7% off the 12-month high
vs DCF fair value3323% aboveest. fair value ~$2
What the price assumes: free cash flow growing over 60% next year, slowing to 4% a year by year ten — vs a starting rate of ~25% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Quality signals
Gross profitability40% · A-gross profit ÷ total assets — not in the score
ROIC8.0% · C+return on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Biotechnology · market cap $8.5b. 7% off the 52-week high of $59.30. Revenue growing +76% — in hypergrowth territory. 7 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $69.71 (implying +26% upside).
Moat
Net margin 55% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 73% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.80 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 10.6x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $69.71 (7-analyst consensus) — fundamentals + valuation re-rating. 5 yr $102.07 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $151.41 if current growth sustains into durable earnings power.
TGTX vs the Top Picks average
Pillar
TGTX
Book avg
Diff
Quality
58
83
-25
Growth
72
89
-17
Value
27
76
-49
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · TGTX
Trend
-7.8 over 82 daily scores
From 56.1 (Jun 22) → 48.3 (now)
One point per daily run; read From → To for the actual range.
TGTX at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-8.7%
90-day change
-10.0%
Forward EPS estimate
$2.71
Over the last 90 days, what analysts expect TGTX to earn is materially lower (-10.0%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · TGTX
$
%
%
Shares to buy
36
Position size
$1,993
4.0% of portfolio
Stop price
$41.53
25% below $55.37
$ at risk if stopped
$498.33
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
TG Therapeutics, Inc. (TGTX): score, valuation & FAQ
TG Therapeutics, Inc. (TGTX) is a Biotechnology company that scores 48.3 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and P/E (B+), while FCF (C-) rate weaker. On valuation, TGTX sits about 3323% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten.
Is TGTX a good stock to buy?
Bull Rankings scores TGTX 48.3 out of 100 on its quality-growth model, which is a below-average reading. That is driven by Rev (A) and P/E (B+). A score is a quantitative screen of TG Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does TGTX score 48.3 on Bull Rankings?
The score leans on growth at 71.8 out of 100, with value the weakest pillar at 27.1 — the three combine geometrically, so a weak one cannot be papered over by a strong one. TGTX earns its highest marks on Rev (A) and P/E (B+), and is held back by FCF (C-). Each signal is graded against sector-aware thresholds rather than one absolute bar, so TGTX is measured against Biotechnology peers, not against the market as a whole.
Is TGTX overvalued or undervalued?
Based on $55.37, TGTX sits about 3323% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten. It trades at a 19.4x P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in TGTX?
Beta 1.80 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 10.6x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.